Molecular  therapy for Non-alcoholic fatty liver disease (NAFLD): Melatonin promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 24/March/2018, 12.32 am

Spread the love
        

Significance of the study:

Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.

From Research findings to Therapeutic opportunity:

This study suggests a melatonin-based therapy for NAFLD. Melatonin, by increasing the expression of its target gene, it may suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol and total cholesterol levels; (2) attenuate lipid deposition in liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus,  Melatonin or its activators may be used to treat NAFLD.

Figure 1. Mechanistic insights into how Melatonin decreases the expression of HMGCR
Figure 2. Melatonin attenuates the progression of NAFLD

[easy_payment currency=”USD”]

 

 

 

 

 

 

 

Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Melatonin decrease the expression of HMGCR?

Amount: $300#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org

* Research cooperation

References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Molecular  therapy for Non-alcoholic fatty liver disease (NAFLD): Melatonin promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 24/March/2018, 12.31 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org


Spread the love